What Drives Reimbursement for Biomarker Testing?

As the policy and coverage landscape evolves, healthcare professionals can benefit from understanding the implications of coverage policies for appropriate biomarker testing for their patients.

Target Audience

This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with solid tumors.

Learning Objectives

Following this program, participants should be able to:

  • Recognize factors that influence access to biomarker testing.
  • Identify challenges to biomarker testing encountered by patients with cancer.
  • Describe the implications of legislative policies for coverage of appropriate biomarker testing for patients with cancer.

You may also be interested in

Supportive Oncology Care

Many health care professionals have had limited education on supportive care topics and have learned on the job. The guidelines and literature continue to advance supportive oncology care.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca; Exact Sciences; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Natera; Novartis; and Sanofi. This activity is supported by educational funding provided by Amgen. This activity is supported by an independent educational grant from Merck & Co., Inc.

Course summary
Available credit: 
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation
Course opens: 
06/15/2023
Course expires: 
06/15/2024
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2023 Congress: Biomarkers in Solid Tumors

Moderator
Crystal S. Denlinger, MD
National Comprehensive Cancer Center

Panelists
Devon Adams, RN, MPH
American Cancer Society Cancer Action Network

Gabriel A. Bien-Willner, MD, PhD
Palmetto GBA

Lisa Schlager
FORCE: Facing Our Risk of Cancer Empowered

Howard (Jack) West, MD
City of Hope National Medical Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Presenting Faculty

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

Lisa Schlager

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Devon Adams, RN, MPH  
Amgen Inc.: Grant/Research Support  
Bayer HealthCare: Grant/Research Support 
Blueprint Medicines: Grant/Research Support 
Bristol-Myers Squibb Company: Grant/Research Support 
EMD Serono: Grant/Research Support 
Foundation Medicine, Inc.: Grant/Research Support 
Genentech, Inc.: Grant/Research Support 
Janssen Pharmaceutica Products, LP: Grant/Research Support 
Merck & Co., Inc.: Grant/Research Support 
NeoGenomics Laboratories, Inc.: Grant/Research Support 
Pfizer Inc.: Grant/Research Support 
sanofi-aventis U.S.: Grant/Research Support 

Gabriel A. Bien-Willner, MD, PhD 
Guardant Health: Equity Interest/Stock Options 
Illumina, Inc.: Scientific Advisor 
Merck & Co., Inc.: Scientific Advisor

Crystal S. Denlinger, MD 
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support 
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support 
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support 
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor 
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor 
Zymeworks: Scientific Advisor; Grant/Research Support 

Howard (Jack) West, MD  
Amgen Inc.: Consulting Fee 
AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau
Boehringer Ingelheim GmbH: Consulting Fee 
Daiichi-Sankyo Co.: Consulting Fee  
Genentech/Roche: Consulting Fee  
Merck & Co., Inc.: Consulting Fee; Product/Speakers Bureau  
Mirati Therapeutics, Inc.: Consulting Fee  
Regeneron Pharmaceuticals, Inc.: Consulting Fee 
Summit Therapeutics Inc.: Consulting Fee 
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Congress Co-Moderators

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.  

Anthony J. Olszanski, MD, RPh  
Bristol-Myers Squibb Company: Scientific Advisor 
Eisai Inc.: Scientific Advisor  
InstilBio: Scientific Advisor  
Merck & Co., Inc.: Scientific Advisor  
Nektar Therapeutics: Scientific Advisor  
Novartis Pharmaceuticals Corporation: Scientific Advisor  
Oncosec Immunotherapies: Scientific Advisor 
Pfizer Inc.: Honoraria 
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor 

Tuya Pal, MD 
Natera, Inc.: Scientific Advisor 

NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated. 

Crystal S. Denlinger, MD 
Agios, Inc.: Grant/Research Support 
Amgen Inc.: Grant/Research Support 
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
BeiGene: Scientific Advisor; Grant/Research Support 
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support 
Eli Lilly and Company: Grant/Research Support 
Exelixis Inc.: Grant/Research Support 
Genmab: Grant/Research Support 
MacroGenics: Grant/Research Support 
MedImmune Inc: Grant/Research Support 
Merck & Co., Inc.: Scientific Advisor 
sanofi-aventis U.S.: Grant/Research Support 
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor 
Zymeworks: Scientific Advisor; Grant/Research Support 

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.25 contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.25 contact hours (0.125 CEUs) of continuing education credit. UAN: JA4008196-0000-23-087-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until June 15, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing